Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
Multicentric Castleman disease is a systemic lymphoproliferative disease with incomplete understood etiology. The various renal complications of this disease may include minimal change disease, mesangial proliferative glomerulonephritis, membranous glomerulonephritis and nephrotic syndrome, caused by secondary amyloidosis. In several reported cases of localized Castleman disease associated with renal amyloidosis and nephrotic syndrome, resection of organs involved by lymphoid proliferation resulted in complete remission. However, therapy of multicentric Castleman disease with renal amyloidosis is not well-established. We treated a case of a 39-year-old woman with multicentric Castleman disease complicated by nephrotic syndrome caused by secondary AA amyloidosis. The patient underwent autologous peripheral blood stem cell transplantation (auto-PBSCT), achieving complete remission. Autologous stem cell transplantation may be an attractive choice in therapy for refractory multicentric Castleman disease.
Ogita
M
M
Kidney Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan. m-ogita@sa2.so-net.ne.jp
Hoshino
J
J
Sogawa
Y
Y
Sawa
N
N
Katori
H
H
Takemoto
F
F
Ubara
Y
Y
Hara
S
S
Miyakoshi
S
S
Takaichi
K
K
D000328:Adult; D000686:Amyloidosis / Q000209:etiology* / Q000628:therapy; D005871:Castleman Disease / Q000150:complications* / Q000628:therapy*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D019653:Myeloablative Agonists / Q000008:administration & dosage; D009404:Nephrotic Syndrome / Q000209:etiology* / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation
D019653:Myeloablative Agonists; D008558:Melphalan